Stockle - the stock oracle

Arcadia Biosciences, Inc.

NYSE:RKDA
US$0.287Close 7 Oct 2026 · delayed

Past year: ▼ 92%(28.0c – 3.73 USD)

Market cap
A$978k
Shares on issue
2.4m
Story beats
26 since 2015
Last event
10 Aug 2026

Announcements, explained

Each one in plain English, with the numbers worked through for a shareholder.

15 June 2026capital raising announcement▼ BadMajor

Arcadia raised about $4 million in another pre-funded-warrant-and-options private placement, priced at $1.0299 per unit -- continued reliance on dilutive, option-heavy financing to stay funded after the failed Roosevelt merger.

Discuss in chat

14 Jan 2026capital raising announcement▼ BadMajor

Weeks after the Roosevelt deal collapsed, Arcadia induced holders of older investment options (originally priced at $9.00, issued across four financings from Dec 2020 through Mar 2023) to exercise at a steeply reduced $2.575, raising about $2.1 million -- in exchange, holders got new options at an even lower $2.325 strike -- another round of option-recycling to raise emergency cash.

Discuss in chat

3 Mar 2023capital raising announcement▲ GoodMajor

Arcadia raised capital in a private placement at $9.00/share (666,334 shares or pre-funded warrants) plus Series A and Series B investment options -- pricing consistent with a reverse stock split having taken effect since the 2022 sub-$1 financings.

Discuss in chat

16 Aug 2022capital raising announcement▼ BadMajor

Arcadia raised capital via a registered direct offering at $1.05876/share (4,722,506 shares or pre-funded warrants), with separately-priced long-dated investment options -- pricing now hovering near the $1.00 level that periodically triggers Nasdaq bid-price deficiencies.

Discuss in chat

29 Jan 2021capital raising announcement▲ GoodMajor

Arcadia's largest financing yet: 7,876,784 shares at $3.1925 plus warrants for another 3.9 million shares, with a registration rights agreement obligating the company to register the shares for resale by specific deadlines or pay liquidated damages.

What it means for a shareholder

7.9m new shares at US$3.19 to raise about US$25.1m. That's 37% dilution: every existing holder's slice gets 37% smaller. If you held US$1,000 of shares (313 at the issue price), your slice goes from 0.00233% to 0.00147% of the company. To keep it you'd need 183 more shares - about US$584 at the issue price.

Create a free account to see this worked out for your own holding.

Discuss in chat

22 Dec 2020capital raising announcement▼ Bad

Another Wainwright-placed offering, 2,618,658 shares at $2.93 -- the lowest price yet in this recurring financing pattern.

What it means for a shareholder

2.6m new shares at US$2.93 to raise about US$7.7m. That's 19% dilution: every existing holder's slice gets 19% smaller. If you held US$1,000 of shares (341 at the issue price), your slice goes from 0.00315% to 0.00254% of the company. To keep it you'd need 83 more shares - about US$243 at the issue price.

Create a free account to see this worked out for your own holding.

Discuss in chat

8 July 2020capital raising announcement▲ Good

That exercise closed, raising the expected $2.55 million.

Discuss in chat

6 July 2020capital raising announcement● Neutral

A further warrant-inducement exercise (641,416 shares, price cut from $10.7258 to $3.975, ~$2.55 million expected) -- proceeds earmarked specifically to cover Arcadia's funding obligations to Verdeca, its joint venture with Bioceres.

Discuss in chat

18 May 2020capital raising announcement▲ Good

The warrant exercise closed, raising the expected $6.82 million and issuing 1,392,345 shares; Wainwright received its own warrants and cash/management fees as placement agent.

What it means for a shareholder

1.4m new shares at about US$4.90 to raise about US$6.8m. That's 14% dilution: every existing holder's slice gets 14% smaller. If you held US$1,000 of shares (204 at the issue price), your slice goes from 0.00236% to 0.00203% of the company. To keep it you'd need 33 more shares - about US$162 at the issue price.

Create a free account to see this worked out for your own holding.

Discuss in chat

14 May 2020capital raising announcement▼ Bad

Arcadia induced holders of its 2018 warrants to exercise early by cutting the exercise price from $9.94 to $4.90, expected to raise about $6.82 million -- in exchange, the holders received new warrants at a lower $4.775 strike, another round of the same warrant-recycling pattern.

Discuss in chat

9 Sept 2019capital raising announcement▲ Good

A further Wainwright-placed offering at $7.52/share, with warrant coverage reduced to 50% of shares sold -- somewhat improved terms versus the June raise.

Discuss in chat

14 June 2019capital raising announcement▼ Bad

Another Wainwright-placed offering, 1,489,575 shares at $4.91 -- roughly half the per-share price of a year earlier, reflecting the stock's continued decline.

What it means for a shareholder

1.5m new shares at US$4.91 to raise about US$7.3m. That's 24% dilution: every existing holder's slice gets 24% smaller. If you held US$1,000 of shares (204 at the issue price), your slice goes from 0.00426% to 0.00325% of the company. To keep it you'd need 64 more shares - about US$314 at the issue price.

Create a free account to see this worked out for your own holding.

Discuss in chat

14 June 2018capital raising announcement▲ Good

Arcadia raised more capital -- 1,392,345 shares at $9.93 plus matching warrants -- via a shelf takedown, with H.C. Wainwright engaged as placement agent, a relationship that would recur in nearly every subsequent financing.

What it means for a shareholder

1.4m new shares at US$9.93 to raise about US$13.8m. That's 36% dilution: every existing holder's slice gets 36% smaller. If you held US$1,000 of shares (101 at the issue price), your slice goes from 0.00406% to 0.0026% of the company. To keep it you'd need 57 more shares - about US$566 at the issue price.

Create a free account to see this worked out for your own holding.

Discuss in chat

23 Mar 2018capital raising announcement▼ BadMajor

Arcadia raised capital in a structured private placement -- 300,752 shares plus warrants initially priced at $45.75 -- with unusual downward-resetting pricing mechanics that could cut the purchase/exercise price to as low as $8.322 depending on later trading prices, a sign of a weak bargaining position typical of a company under Nasdaq compliance pressure.

Discuss in chat